​

Haemonetics (HAE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HAE Stock Forecast

Haemonetics (HAE) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $75.33, with a high of $89.00 and a low of $67.00. This represents a -5.65% decline from the last price of $79.84.

$65 $71 $77 $83 $89 $95 High: $89 Avg: $75.33 Low: $67 Last Closed Price: $79.84

HAE Stock Rating

Haemonetics stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (52.38%), 10 Hold (47.62%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 0 10 11 Strong Sell Sell Hold Buy Strong Buy

HAE Price Target Upside V Benchmarks

TypeNameUpside
StockHaemonetics-5.65%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks19.52%

Price Target Trends

1M3M12M
# Anlaysts-312
Avg Price Target-$75.33$84.08
Last Closing Price$79.84$79.84$79.84
Upside/Downside--5.65%5.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26443--11
May, 26434--11
Apr, 26434--11
Mar, 26434--11
Feb, 26434--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 12, 2026Barrington$89.00$52.2470.37%11.47%
May 08, 2026David RescottRobert W. Baird$67.00$51.5529.97%-16.08%
Apr 13, 2026Anthony PetroneMizuho Securities$70.00$57.3921.97%-12.32%
Feb 06, 2026Robert W. Baird$81.00$61.4031.92%1.45%
Feb 06, 2026Barrington$94.00$65.0244.57%17.74%
Feb 06, 2026Mizuho Securities$80.00$65.0223.04%0.20%
Jan 12, 2026Barrington$93.00$82.0313.37%16.48%
Dec 17, 2025Mizuho Securities$90.00$81.1110.96%12.73%
Dec 15, 2025Robert W. Baird$99.00$80.3323.24%24.00%
Nov 14, 2025Andrew CooperRaymond James$90.00$73.9121.77%12.73%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 28, 2026CitigroupNeutralNeutralhold
May 22, 2026Bank of America SecuritiesNeutralBuyupgrade
May 12, 2026CitigroupOutperformOutperformhold
Feb 06, 2026CitigroupNeutralNeutralhold
Dec 15, 2025NeedhamBuyHolddowngrade
Dec 11, 2025CitigroupUnderperformNeutraldowngrade
Nov 14, 2025Raymond JamesOutperformOutperformhold
Nov 06, 2025BTIGBuyBuyhold
Aug 11, 2025Raymond JamesStrong BuyOutperformdowngrade
Aug 07, 2025NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$0.85$2.27$2.32$3.31$2.05--
Avg Forecast$2.53$2.97$3.96$4.59$5.28$6.07$7.55
High Forecast$2.59$3.02$4.03$4.60$5.36$6.66$7.68
Low Forecast$2.50$2.92$3.95$4.57$5.20$5.34$7.42
Surprise %-66.40%-23.57%-41.41%-27.89%-61.17%--

Revenue Forecast

$950M $1B $1B $1B $2B $2B Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$993.20M$1.17B$1.31B$1.36B$1.33B--
Avg Forecast$986.15M$1.15B$1.30B$1.39B$1.44B$1.57B$1.81B
High Forecast$1.00B$1.17B$1.31B$1.40B$1.46B$1.57B$1.84B
Low Forecast$975.63M$1.14B$1.28B$1.38B$1.41B$1.57B$1.79B
Surprise %0.71%1.19%1.08%-2.36%-7.23%--

Net Income Forecast

$-50M $40M $130M $220M $310M $400M Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27 Mar 28
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28
Reported$43.38M$115.40M$117.56M$167.68M$97.31M--
Avg Forecast$-3.10M$152.47M$123.81M$235.67M$271.40M$308.39M$388.05M
High Forecast$3.75M$155.16M$148.57M$236.44M$275.29M$342.43M$394.89M
Low Forecast$-9.95M$149.83M$99.05M$234.90M$267.50M$274.35M$381.33M
Surprise %-1498.81%-24.31%-5.05%-28.85%-64.15%--

HAE Forecast FAQ

Is Haemonetics stock a buy?

Haemonetics stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 10 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Haemonetics is a favorable investment for most analysts.

What is Haemonetics's price target?

Haemonetics's price target, set by 21 Wall Street analysts, averages $75.33 over the next 12 months. The price target range spans from $67 at the low end to $89 at the high end, suggesting a potential -5.65% change from the previous closing price of $79.84.

How does Haemonetics stock forecast compare to its benchmarks?

Haemonetics's stock forecast shows a -5.65% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical instruments & supplies stocks industry (19.52%).

What is the breakdown of analyst ratings for Haemonetics over the past three months?

  • June 2026: 36.36% Strong Buy, 36.36% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 36.36% Strong Buy, 27.27% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 36.36% Strong Buy, 27.27% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.

What is Haemonetics’s EPS forecast?

Haemonetics's average annual EPS forecast for its fiscal year ending in March 2027 is $6.07, marking a 196.10% increase from the reported $2.05 in 2026. Estimates for the following years are.

What is Haemonetics’s revenue forecast?

Haemonetics's average annual revenue forecast for its fiscal year ending in March 2027 is $1.57B, reflecting a 17.55% increase from the reported $1.33B in 2026. The forecast for.

What is Haemonetics’s net income forecast?

Haemonetics's net income forecast for the fiscal year ending in March 2027 stands at $308.39M, representing an 216.92% increase from the reported $97.31M in 2026. Projections indicate .